ArticleThe American journal of cardiology2021
Lipoprotein(a) Testing Patterns in a Large Health System.
Article in The American journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Implementation and Assessment of a Lipoprotein(a) Curriculum for Internal Medicine Residents: A Longitudinal Study.Cureus · 2025Article
- Factors Associated with Lipoprotein(a) Testing Among Multiethnic Individuals.Journal of general internal medicine · 2025Article
- Evaluation of a Machine Learning-Guided Strategy for Elevated Lipoprotein(a) Screening in Health Systems.Circulation. Genomic and precision medicine · 2025Article
- Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing.Frontiers in cardiovascular medicine · 2025Article
- Temporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023.American journal of preventive cardiology · 2024Article
- Lipoprotein (a) testing patterns among subjects with a measured lipid panel: The Mayo Clinic experience.American journal of preventive cardiology · 2024Article
- Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems.Journal of the American Heart Association · 2024Article
- Testing practices and clinical management of lipoprotein(a) levels: A 5-year retrospective analysis from the Johns Hopkins Hospital.American journal of preventive cardiology · 2024Article
- Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000-23.European journal of preventive cardiology · 2024Article
- Article
- Development and multinational validation of an algorithmic strategy for high Lp(a) screening.Nature cardiovascular research · 2024Article
- Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations.American heart journal plus : cardiology research and practice · 2024Article
- Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes.American journal of preventive cardiology · 2023Article
- Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice.Journal of clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Lipoprotein (a) [Lp(a)] is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). As directed therapy for Lp(a) emerges, it is important to understand patterns of Lp(a) testing in routine clinical practice. We set out to characterize Lp(a) testing across a large academic health system. Using electronic health record (EHR) data from 2014 to 2019, we compared patients who underwent Lp(a) testing to date-matched peers who had low density lipoprotein (LDL-C) assessment alone. We analyzed ordering provider characteristics and rates of initiation of new lipid lowering therapy (LLT) within 12 months after testing. Of 1,296 adults with Lp(a) test results, 629 (48.5%) had prior history of ASCVD and 667 (51.4%) did not. Compared with those with LDL-C testing alone, individuals who underwent Lp(a) testing were more like to have a myocardial infarction or ischemic stroke at a young age and multiple prior cardiovascular events. Though the majority of Lp(a) tests were ordered in outpatient encounters, a higher proportion of Lp(a) tests compared with LDL-C tests were performed in the inpatient setting. Neurology and psychiatry were the most common specialty to order Lp(a) tests in our cohort. There was a significantly increased initiation of LLT after Lp(a) testing compared with LDL-C testing across all medication types. Consistent with guidelines, Lp(a) testing is used in those with early onset ASCVD, and among those with multiple cardiovascular events. Lp(a) testing is associated with more aggressive LLT in following year. Further research is needed to characterize Lp(a) testing across larger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.